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ABSTRACT
Background: Worldwide, coronary heart
disease accounts for 7 million deaths each
year. In Sweden, acute coronary syndrome
(ACS) is a leading cause of hospitalization and
is responsible for 1 in 4 deaths.
Objective: The aim of this analysis was to assess
the cost-effectiveness of rivaroxaban 2.5 mg
twice daily (BID) in combination with
standard antiplatelet therapy (ST-APT) versus
ST-APT alone, for the secondary prevention of
ACS in adult patients with elevated cardiac
biomarkers without a prior history of
stroke/transient ischemic attack (TIA), from a
Swedish societal perspective, based on clinical
data from the global ATLAS ACS 2-TIMI 51 trial,
literature-based quality of life data and costs
sourced from Swedish national databases.
Methods: A Markov model was developed to
capture rates of single and multiple myocardial
infarction (MI), ischemic and hemorrhagic
stroke, thrombolysis in myocardial infarction
(TIMI) major, minor, and ‘‘requiring medical
attention’’ bleeds, revascularization events, and
associated costs and utilities in patients who
were stabilized after an initial ACS event.
Efficacy and safety data for the first 2 years
came from the ATLAS ACS 2-TIMI 51 trial.
Long-term probabilities were extrapolated using
safety and effectiveness of acetylsalicylic acid
data, which was estimated from published
literature, assuming constant rates in time.
Future cost and effects were discounted at
3.0%. Univariate and probabilistic sensitivity
analyses were conducted.
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Results: In the base case, the use of rivaroxaban
2.5 mg BID was associated with improvements
in survival and quality-adjusted life years
(QALYs), yielding an incremental cost per
QALY of 71,246 Swedish Krona (SEK) (€8045).
The outcomes were robust to changes in inputs.
The probabilistic sensitivity analysis
demonstrated rivaroxaban 2.5 mg BID to be
cost-effective in [99.9% of cases, assuming a
willingness-to-pay threshold of SEK 500,000
(€56,458).
Conclusion: Compared with ST-APT alone, the
use of rivaroxaban 2.5 mg BID in combination
with ST-APT can be considered a cost-effective
treatment option for ACS patients with elevated
cardiac biomarkers without a prior history of
stroke/TIA in Sweden.
Funding: Bayer Pharma AG.
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INTRODUCTION
Coronary heart disease (CHD) is a major public
health concern; it is the leading cause of
mortality worldwide, accounting for more
than 7 million deaths each year [1]. The
majority of CHD-related deaths are due to
acute coronary syndrome (ACS) or resulting
complications [2, 3]. In Sweden, 1 in 4 deaths
are estimated to be due to ACS [4]. ACS is based
on the underlying pathophysiology of
thrombosis, which is induced by the rupture
or erosion of vulnerable coronary plaque. Such
a rupture will cause the formation of a blood
clot, which subsequently blocks the artery,
leading to a sudden or substantial reduction in
the coronary blood flow. Manifestations of ACS
typically fall into three categories: ST-segment
elevation myocardial infarction (STEMI), non-
ST-segment elevation myocardial infarction
(NSTEMI) and unstable angina (UA). All three
are associated with a (very) high, moderate and
(very) low degree of obstruction to myocardial
perfusion and severity of myocardial ischemia,
respectively. Electrocardiograms (ECGs) and
cardiac biomarkers (e.g., troponin) can be used
to differentiate between the types of ACS (i.e.,
between [N]STEMI and UA) and these play a
crucial role in risk stratification because
biomarker elevation can help to identify
myocardial cellular damage and potentially
predict short-term outcomes of subsequent
myocardial infarction (MI) and death [5, 6].
Current European guidelines recommend
dual antiplatelet therapy of acetylsalicylic acid
(ASA) plus a P2Y12 inhibitor (i.e., ticagrelor,
prasugrel, ticlopidine or clopidogrel) to reduce
the risk of thrombus formation in ACS patients
[7, 8]. Dual antiplatelet therapy has proven
efficacy in reducing the likelihood of secondary
cardiovascular (CV) events, with an increase in
the rate of major bleeding [8]. Despite such ‘dual
antiplatelet’ prophylaxis, 20% of patients die
within 5 years of an ACS event. The vast
majority of these deaths occur after discharge
from hospital for the initial ACS event (the index
event) [5, 9]. To further reduce this burden,
several novel oral anticoagulants (apixaban,
dabigatran and rivaroxaban) have been
investigated for the prevention of secondary
events in the ACS indication [8, 10, 11].
The Anti-Xa Therapy to Lower
Cardiovascular Events in Addition to Standard
Therapy in Subjects with Acute Coronary
Syndrome 2-Thrombolysis in Myocardial
Infarction 51 (ATLAS ACS 2-TIMI 51) trial
(Clinicaltrials.gov identifier: NCT00809965)
was a global multicenter, randomized, double-
blind, placebo-controlled, event-driven study.
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The design and clinical results have been
reported elsewhere [11]. The trial randomized
15,526 patients with a recent ACS event to
receive twice-daily (BID) doses of 2.5 mg or
5 mg rivaroxaban in combination with standard
antiplatelet therapy (ST-APT), defined as
acetylsalicylic acid (ASA) alone or ASA in
combination with clopidogrel or ticlopidine,
versus ST-APT alone. Rivaroxaban 2.5 mg BID in
combination with ST-APT was shown to reduce
the risk of the composite endpoint of death
from CV causes, MI or stroke (hazard ratio
[HR] = 0.84; 95% confidence interval [CI]
0.72–0.97); the risk reduction in all-cause
mortality (HR = 0.68; 95% CI 0.53–0.87) was
achieved without an increase in the risk of fatal
bleeding (HR = 0.67; 95% CI 0.24–1.89) [11].
Rivaroxaban 2.5 mg BID has marketing
approval in Europe for an adult post-ACS
patient population with elevated cardiac
biomarkers and without a prior history of
stroke or transient ischemic attack (TIA). The
aim of this research was to estimate the cost-
effectiveness of rivaroxaban 2.5 mg BID when
used as secondary prevention versus ST-APT
alone in such patients, from a Swedish societal
perspective.
METHODS
The current study consists of a cost-
effectiveness analysis (CEA) of secondary
prevention in adult ACS patients with elevated
cardiac biomarkers without a prior history of
stroke or TIA. This article is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
Patients enter the model following
stabilization of their ACS event which is
defined according to the ATLAS ACS-TIMI 51
study as the time, up to 7 calendar days after
the subject has been hospitalized for the index
ACS event, when the initial inpatient
treatment (including revascularization
procedures and parenteral anticoagulant
therapy) would have been discontinued. To
inform the design of the model and specify
model inputs, formal systematic literature
reviews of economic evaluations, clinical data
from epidemiological studies and clinical trials,
quality of life data, and costs and resource use
were performed according to published
guidelines [12, 13]. The searches
encompassed, among other sources, electronic
medical databases commonly prescribed by
HTA authorities (Medline, Medline in-process,
Embase, EconLit, National Health Service
Economic Evaluation Database, Health
Technology Assessment Database, and
Cochrane Library [CENTRAL and database of
systematic reviews]), and conference
proceedings of most important cardiovascular
and health economic conferences (American
Heart Association [AHA], European Society of
Cardiology [ESC], American College of
Cardiology [ACC], American College of Chest
Physicians [ACCP] and International Society
for Pharmacoeconomics and Outcomes
Research [ISPOR]). The full details of the
literature review are provided in the online
appendix to this article on the publisher’s
website.
Clinical event risks, safety and treatment
discontinuation rates from the ATLAS ACS
2-TIMI 51 trial, combined with real-world
evidence to estimate event rates beyond the
trial period, were used to evaluate the long-term
cost-effectiveness of treating patients with
rivaroxaban 2.5 mg BID in combination with
ST-APT. The clinical data, used to inform the
first 2 years of the model, were estimated from
the intent-to-treat (ITT) trial population,
comprising adult patients with elevated cardiac
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biomarkers without a prior history of stroke or
TIA, which represents the European label for
rivaroxaban. A maximum treatment duration of
2 years was assumed for rivaroxaban 2.5 mg BID
in the analysis. To comply with current clinical
guidelines for ACS, the maximum treatment
duration for clopidogrel or ticlopidine in both
arms of the analysis was 1 year [7, 8].
Model Structure
With consideration of ESC guidelines [8], a
Markov model was constructed to assess the
cost-effectiveness of rivaroxaban 2.5 mg BID in
combination with ST-APT versus ST-APT alone.
The underlying model structure applied was
similar in design to previously published
economic evaluations in ACS and wider CV
disease [14–17].
The Markov model was constructed in
Microsoft Excel 2010 with a 40-year (i.e.,
lifetime) horizon to simulate the costs and
benefits of rivaroxaban 2.5 mg BID treatment
in combination with ST-APT. The model
considered a patient cohort with an average
age of 62 years, to replicate the average age of
patients with elevated biomarkers without a
prior history of stroke or TIA in the ATLAS ACS
2-TIMI 51 trial.
The model consisted of 16 health states
which represent the occurrence of single and
multiple cardiovascular events over time
(Fig. 1). Health states separately describing
MI, ischemic stroke (IS), hemorrhagic stroke/
Event Free
Bleeding
Major 
Minor
Med A.
Revasc.
PCI
CABG
Cycle length = 12 weeks (0-2 years) and 6 months (2-40 years)
1 Event
• MI
• IS
• HS/ICH
2 Events
• MI + MI
• IS + IS
• HS/ICH + HS/ICH
• MI + IS
• MI + HS/ICH
• IS + HS/ICH
3 Events
Events are not traced 
for the ‘3 events’ state 
due to low numbers of 
observaons
Bleeding
Major 
Minor
Med A.
Bleeding
Major 
Minor
Med A.
Bleeding
Major 
Minor
Med A.
Revasc.
PCI
CABG
Revasc.
PCI
CABG
Revasc.
PCI
CABG
Death
Fatal MI      Fatal IS      Fatal HS/ICH      OCD (inc. fatal bleeding)      NCD
Fig. 1 Markov model structure showing 16 health states;
bleedings and revascularizations were considered as tran-
sient health states with a one-off cost and short-term
disutility impact. CABG coronary artery bypass graft, HS
hemorrhagic stroke, ICH intracranial hemorrhage, Incl.
including, IS ischemic stroke, MI myocardial infarction,
Med Att. medical attention, NCD non-cardiovascular
death, OCD other cardiovascular death, PCI percutaneous
coronary intervention
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intracranial hemorrhage (HS/ICH), and death
define the model framework. These are key
events that a patient might experience after an
ACS. Within each of the non-fatal event states
there are tunnel states representing the time
since the event. These allow for variable
transition probabilities, costs and utility
decrements following a cardiovascular event
[11, 18, 19]. Fatal events in the model,
although grouped together in the final
outcome, consider fatal MI, fatal IS, fatal HS/
ICH, other CV death and non-CV death as
distinct events in terms of event probabilities
and costs. Fatal bleeding events are considered
within the ‘other CV death’ health state and
ICHs are captured in the ‘HS/ICH’ health state.
Other non-fatal bleeds, including thrombolysis
in myocardial infarction (TIMI) major, TIMI
minor and TIMI requiring medical attention
bleeding events, are associated with a one-off
cost and short-term disutility, and were thus
considered transient health states. Percutaneous
coronary interventions (PCI) and coronary
artery bypass grafts (CABG) were also included
as transient health states. All short-term clinical
data were taken from the European label
population subgroup of ATLAS ACS 2-TIMI 51
trial, that is, patients with elevated biomarkers
without a prior history of stroke/TIA. Clinical
results for this population have been published
elsewhere [20]. A full and detailed description of
each health state, and how patients may
transition between these, is provided in Table 1.
The model considered 12 weekly cycles in
the first 2 years (observation period) in line with
study visits in ATLAS ACS 2-TIMI 51, and 6
monthly cycles thereafter (extrapolation
period), to allow for variable transition
probabilities, costs and utilities as patients
recover from the initial event and their risk of
secondary events decreases [21]. A half-cycle
correction was applied to reflect the continuous
nature of the occurrence of transitions during
each cycle by assuming that, on average, all
transitions occur halfway through any
particular cycle. At the end of each model
cycle, patients remained in their current
health state, experienced a subsequent CV
event or died. After an event, patients accrued
additional costs and utility decrements in
subsequent cycles until they transitioned to a
new health state. The model distinguished
between three phases within each non-fatal
health state: a period comprising the first
6 months after the event, a period comprising
the second 6 months after the event, and
subsequent 6-month periods (post 12 months).
Therefore, the first two phases were
incorporated as tunnel states in which patients
can remain for one (6-month) cycle only.
Model Assumptions
The model assumed there was no treatment
effect associated with rivaroxaban or
clopidogrel or ticlopidine after treatment
discontinuation. In line with treatment
guidelines, ASA monotherapy was assumed to
be continued after discontinuation of all other
treatment(s) for the remainder of the model.
Rivaroxaban was assumed to be prescribed for a
maximum of 2 years. Clopidogrel and
ticlopidine were assumed to be discontinued
in both treatment arms after 1 year. As
ticlopidine is not available in Sweden for the
treatment of ACS patients, it was assumed that
all patients who received ticlopidine in the
ATLAS ACS 2-TIMI 51 clinical trial (\1% of
patients) were subsequently treated with
clopidogrel, without affecting the overall
clinical outcomes.
Different assumptions regarding post-event
treatment discontinuation rates were applied to
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the first 12 months and subsequent 12 months
of the modeled time period.
• Discontinuations of rivaroxaban and/or
clopidogrel or ticlopidine for the first year
were reflective of the discontinuation rates
observed in the clinical trial.
• Based on expert opinion, rivaroxaban
discontinuation in the second year of
treatment is predicted to be higher in real-
life practice than observed in the clinical
study.
• During the second year of treatment, an
overall discontinuation rate of 81% was
assumed. Efficacy and treatment costs for
rivaroxaban in the second year of the
model were adjusted accordingly. This
assumption is conservative and reflective
of the informed decision about therapy
physicians make in the second year of
treatment.
Revascularizationandnon-ICHbleedingevents
were assumed to only occur during the observation
period (in accordance with the specified length of
treatment in each arm) as the rates would be
considered equal after rivaroxaban and ST-APT
discontinuation, and their impact on the
incremental outcomes negligible after the
observation period. The disutility associated with
these events does not exceed one model cycle
length (12 weeks) and were therefore not modeled
as separate health states.
Model Setting
The CEA was performed from a Swedish societal
perspective. The model was run for 40 years
after which less than 1% of patients were still
alive (lifetime horizon). All future costs and
health outcomes were discounted at a rate of
3.0% per year, as recommended by the Swedish
guidelines for economic evaluations [22]. Costs
were expressed in Swedish Krona (SEK) at 2013
prices using the Consumer Price Index (CPI) to
inflate costs where relevant [23]. Direct costs
were captured in the form of direct medical
costs related to antithrombotic treatment and
secondary events. Indirect costs were captured
in the form of productivity losses and costs of
additional life years, constituting a conservative
approach given the age of patients in the model
[24–27]. All costs were also expressed in Euros
(€1 = SEK 8.8561, exchange rate taken on
January 3, 2014) using foreign exchange rates
taken from the European Central Bank (ECB)
[28].
Transition Probabilities
Clinical data from the ATLAS ACS 2-TIMI 51
trial in adults with elevated cardiac biomarkers
without a prior history of stroke/TIA show a
statistically significant reduction in the
combined primary endpoint of CV death, MI
or stroke, with rivaroxaban 2.5 mg twice daily
versus placebo (HR = 0.80, 95%
CI = 0.68–0.94). These data have been reported
elsewhere [20]. Patient-level data considering
each event type separately were used to estimate
transition probabilities for the model. In doing
so, both clinical benefits (such as are seen in the
case of MIs) and increased risks of events (such
as with HS/ICH events) are appropriately
modeled. The data were interpolated using a
parametric, Weibull-based survival analysis to
generate consistent cycle-dependent transition
probabilities, adjusting for potentially
distorting patient drop-out as observed in the
trial (i.e., survival progression after an event
within the later trial observations was not
considered truly reflective of real-world
survival due to low patient numbers
comprising those later trial observations,
thereby resulting in inconsistent estimates for
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Table 1 Description of model health states
Health state Description Transitions possible from this health state
Free of secondary events
following index ACS
event (‘‘event-free’’)
Patients in this health state have not experienced a
secondary cardiovascular event. During each cycle
patients in this health state are at a risk of a non-
fatal or fatal event, or a combination of events
Patients may transition to any other health state
from here
Non-fatal MI Patients enter this health state if their ﬁrst secondary
event (i.e., their ﬁrst event following their index
ACS event) is a non-fatal MI. Within this health
state are tunnel states depending on the time since
the non-fatal MI occurred. When patients enter the
non-fatal MI health state they enter the ﬁrst tunnel
state and they remain here until the next model
cycle. If the patient experiences no further event in
the following cycle they are still within the non-
fatal MI state, but they move to the second tunnel
state, with risks of further events, costs and utilities
associated with the event changing to represent the
improvement in patient’s health as the time since
the event increases. This pattern continues until the
patient reaches the third, and last state associated
with the event they have experienced. Patients will
remain here until they experience another non-fatal
or fatal event which would cause them to move
health states
Patients may transition to any of the following health
states from the non-fatal MI state, regardless of the
time since the MI: two MIs, MI ? IS, MI ? HS/
ICH, 3 events, fatal MI, fatal IS, fatal HS/ICH,
other CV death, or non-CV death
Non-fatal IS Patients enter this health state if their ﬁrst secondary
event is a non-fatal IS. As with the non-fatal MI
state described in the above paragraph, there are
tunnel states depending on the time since the non-
fatal IS occurred
Patients may transition to any of the following health
states from the non-fatal IS state, regardless of the
time since the event: two ISs, MI ? IS, IS ? HS/
ICH, 3 events, fatal MI, fatal IS, fatal HS/ICH,
other CV death, or non-CV death
Non-fatal HS/ICH Patients enter this health state if their ﬁrst secondary
event is a non-fatal HS/ICH. Within this health
state are tunnel states depending on the time since
the non-fatal HS/ICH occurred
Patients may transition to any of the following health
states from the non-fatal HS/ICH state, regardless
of the time since the event: two HS/ICHs,
MI ? HS/ICH, IS ? HS/ICH, 3 events, fatal MI,
fatal IS, fatal HS/ICH, other CV death, or non-CV
death
Non-fatal MI ? non-
fatal MI
This health state contains patients who have
experienced two non-fatal MIs since their index
event. Within this health state are tunnel states
depending on the time since the second non-fatal
MI occurred, as described above for the single event
states
Patients may transition to any of the following health
states from the MI ? MI health state: 3 events,
fatal MI, fatal IS, fatal HS/ICH, other CV death,
or non-CV death
Non-fatal IS ? non-fatal
IS
This health state contains patients who have
experienced two non-fatal ISs since their index
event. As with the MI ? MI state described in the
above paragraph, there are tunnel states depending
on the time since the second event causing a patient
to be in the IS ? IS health state occurred
Patients may transition to any of the following health
states from the IS ? IS health state: 3 events, fatal
MI, fatal IS, fatal HS/ICH, other CV death, or
non-CV death
Non-fatal HS/
ICH ? non-fatal HS/
ICH
This health state contains patients who have
experienced two non-fatal HS/ICHs since their
index event. As with the MI ? MI and IS ? IS
states, within this health state are tunnel states
depending on the time since the second non-fatal
HS/ICH occurred
Patients may transition to any of the following health
states from the non-fatal HS/ICH ? non-fatal
HS/ICH health state: 3 events, fatal MI, fatal IS,
fatal HS/ICH, other CV death, or non-CV death
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transition probabilities for the first 2 years of
the model). The decision to continue treatment
with clopidogrel or ticlopidine in the second
year of the ATLAS ACS 2-TIMI 51 trial was at the
physician’s discretion (reflective of real-life
setting). To comply with European Society of
Table 1 continued
Health state Description Transitions possible from this health state
Non-fatal MI ? non-
fatal IS
This health state contains patients who have
experienced the combination of a non-fatal MI and
a non-fatal IS since their index event. As with the
health states described above where patients have
experienced two secondary events, there are tunnel
states depending on the time since the second event
causing a patient to be in the MI ? IS health state
occurred. The second event may be either the non-
fatal MI or the non-fatal IS, the sequence of events
is not explicitly modeled
Patients may transition to any of the following health
states from the non-fatal MI ? non-fatal IS health
state: 3 events, fatal MI, fatal IS, fatal HS/ICH,
other CV death, or non-CV death
Non-fatal MI ? non-
fatal HS/ICH
This health state contains patients who have
experienced a non-fatal MI and a non-fatal HS/
ICH since their index event. As with the health
states described above where patients have
experienced two secondary events, there are tunnel
states depending on the time since the second event
causing a patient to be in the MI ? HS/ICH
health state occurred. The second event may be
either the non-fatal MI or the non-fatal HS/ICH,
the sequence of events is not explicitly modeled
Patients may transition to any of the following health
states from the non-fatal MI ? non-fatal HS/ICH
health state: 3 events, fatal MI, fatal IS, fatal HS/
ICH, other CV death, or non-CV death
Non-fatal IS ? non-fatal
HS/ICH
This health state contains patients who have
experienced the combination of a non-fatal IS and
a non-fatal HS/ICH since their index event. As
with the health states described above where
patients have experienced two secondary events,
there are tunnel states depending on the time since
the second event causing a patient to be in the
IS ? HS/ICH health state occurred. The second
event may be either the non-fatal IS or the non-
fatal HS/ICH, the sequence of events is not
explicitly modeled
Patients may transition to any of the following health
states from the non-fatal IS ? non-fatal HS/ICH
health state: 3 events, fatal MI, fatal IS, fatal HS/
ICH, other CV death, or non-CV death
Three events Patients in this health state have experienced three
non-fatal events since the index ACS event. The
three events may be any combination of MIs, ISs
and HS/ICHs. Due to the small numbers of
patients who experience three separate non-fatal
events the distinction between the event types is
not made in this health state. However, the
distinction of time periods within this health state
as described for all other non-fatal event health
states above is still considered
Patients may only transition to fatal health states
from the three events state
Fatal events Five fatal event health states (fatal MI, fatal IS, fatal
HS/ICH, other CV death, non-CV death) are
absorbing states. Once a patient enters one of these
5 states they remain there until the end of the
model
No transitions possible
ACS acute coronary syndrome, CV cardiovascular, HS hemorrhagic stroke, ICH intracranial hemorrhage, IS ischemic stroke, MI
myocardial infarction
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Cardiology (ESC) guidelines, and accommodate
the recommended discontinuation of
clopidogrel or ticlopidine after the first year,
transition probabilities were adjusted by a factor
of 1/0.8. This adjustment factor was based on
the relative risk reduction (RRR) for clopidogrel
versus ASA demonstrated in the Clopidogrel in
Unstable angina to prevent Recurrent Events
(CURE) trial [29].
To capture long-term survival rates, transition
probabilities on the effectiveness and safety of
ASA were extrapolated assuming constant rates
in time. The Weibull distribution, chosen to
reflect the fact that patient risk decreases over
time following a qualifying event, is time
dependent and was used to estimate transition
probabilities for each 12-week cycle within the
observation period. Therefore, an average
estimate over multiple cycles in which to base
the extrapolation period was not required. The
last observation from the control arm of the
observation period is used to estimate transition
probabilities applied in the extrapolation period,
with the RRR calculated from CURE used to
model transition probabilities based on ASA
monotherapy use in the long term.
Furthermore, event rates applied in the
extrapolation period were based on, and
corrected for, the increased risk of events due
to aging, initial case fatalities and the reduction
in relative risk of experiencing subsequent events
over time. Swedish life tables provided
probabilities of non-CV death for patients aged
62 years (using an elimination method) [30, 31].
In an aging population, patients with ACS
are at an increased risk of experiencing
subsequent CV events or developing
comorbidities that may contribute to the onset
of future events [6, 32]. The annual age-specific
risks of experiencing fatal and non-fatal events
were taken from Swedish sources (Table 2).
Patients who have experienced an ACS event
are at an elevated risk of experiencing a
subsequent event, typically within the first
6 months following an event, although this
risk diminishes over time [33]. The risk of
suffering a second subsequent event after the
first is assumed to be 1.5 times the risk of
suffering a first subsequent event after the index
event [33]. Initial case fatalities (proportion of
fatal events typically within 28–30 days of
onset) taken from the ATLAS ACS 2-TIMI 51
Table 2 Annual age-speciﬁc increased risk of non-fatal and fatal event estimates used to validate the model within the
extrapolation period
Event % annual age-speciﬁc increase Conﬁdence interval (%) References
Non-fatal MI 5.00 2.50–7.50 [30]
Non-fatal IS 9.10 4.55–13.65 [30]
Non-fatal HS/ICH 5.90 2.95–8.85 [30]
Fatal MI 4.50 2.25–6.75 [30]
Fatal IS 3.10 1.55–4.65 [30]
Fatal HS/ICH 3.10 1.55–4.65 (Assumption based on IS)
OCD 6.80 3.40–10.20 [30]
NCD 5.60 2.80–8.40 [34]
HS hemorrhagic stroke, ICH intracranial hemorrhage, IS ischemic stroke, MI myocardial infarction, NCD non-
cardiovascular death, OCD other cardiovascular death
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clinical trial (MI) and published literature (IS
and HS/ICH) were used to define the probability
that a patient’s first modeled event would result
in a fatality [34].
The Sweden MONitoring of trends and
determinants In CArdiovascular disease
(MONICA) study reported a weighted estimate
of median survival after a first MI (based on
gender distribution) of 15.82 years [35]. The
model was calibrated so that the predicted life
expectancy of patients on ST-APT alone after
the first MI event was 15.82 years.
Resource Use and Costs
The cost of non-fatal MI events is estimated
based on the mean cost per patient taken from a
paper which estimates costs from a Swedish
register, accounting for administrative costs,
hospitalizations, diagnostic work-ups,
interventions and rehabilitation [36]. The
proportion of costs allocated to the first
6 months, second 6 months and post
12 month periods following an event were
based on those reported by Heeg et al. [21].
Based on Heeg et al.’s findings, 43% of the total
costs of MI are accrued in the first 3 months
following the event, 19% are accrued in the
second 3 months, and 38% are accrued in the
remainder of the first year following the event.
The cost of non-fatal IS was calculated based on
the gender-weighted average costs incurred
during an inpatient stay, during outpatient
healthcare, and municipal care after a stroke
event within the first year [37]. Cost estimates
using this information were then applied to the
second year after a stroke event. In the absence
of specific, separate costs for IS and HS/ICH, the
costs were assumed to be the same for the stroke
types. Costs for non-fatal/non-ICH bleeding,
revascularization and all fatal events (except
non-CV death) were taken from the
Socialstyrelsen database [38]. Cost calculations
for the transient health states of bleeding and
revascularizations were estimated by
multiplying the proportion of patients
experiencing the event with the unit cost of
each procedure/treatment. In the absence of
suitable costs for non-CV death, a cost of SEK 0
(€0) was assumed. The daily costs for generic
clopidogrel, ASA and rivaroxaban, taken from
the TLV database, were SEK 1.47 (€0.17), SEK
0.61 (€0.07) and SEK 20.91 (€2.36), respectively;
the lowest available prices in February 2013
were used for generic medications [39]. The
daily drug price is multiplied by the number of
days per model cycle and applied to each living
patient within the specified treatment duration
(Table 3).
Indirect costs included productivity losses
due to the events, calculated using the human
capital method (HCM) as prescribed by the
Swedish authority [22], and the cost of survival
from added life years. The HCM assumes that all
productivity loss due to disease can be
accounted for as indirect costs and reflects the
fact that short-term absence from work due to
medical visits as well as due to events of ACS
patients lead to (indirect) costs for society. This
method is applicable to all patients under the
national age of retirement (65 years in Sweden)
[40]. The cost of daily productivity loss is given
by a12365
   1 þ b1 þ b2ð Þ; where a is the average
monthly salary (SEK 29,000) [22], b1 is the
employer benefit (31.42%) [26] and b2 is the
union benefit (10%) [26]. The resulting daily
cost of SEK 1388 (€152) is then multiplied by
the number of days of productivity loss assumed
per event (Table 4). The cost of added life years
takes into account the difference between
consumption and production for patients of
each modeled age category (Table 5). The costs
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for consumption include health care, social
services, education, general public
consumption and private consumption [24].
The proportion of patients in each age
category is representative of the ATLAS ACS
2-TIMI 51 trial.
Utilities
The ATLAS ACS 2-TIMI 51 trial was not
optimally designed to measure utilities per
health state, thus data from literature was
considered more appropriate. The utility
values for the non-fatal events of MI, IS and
HS/ICH were taken from the Platelet inhibition
and patient Outcomes (PLATO) trial [14]. This
source was selected because it represents a
recent source of utility estimates elicited from
a large number of ACS patients. In addition,
these utility values have been applied in many
recent health technology appraisal submissions
of treatment for ACS, and have been accepted as
a robust source in those submissions. Utility
values for stroke over time were not reported for
the PLATO study. Hence, the best alternative
source identified through the systemic literature
review was used to estimate values for the
second 6 months and later periods [41].
The lengths of disutility associated with
bleeding and revascularization events were
based on literature and expert opinion, and
were assumed to be 30 days for TIMI major
bleeding and PCI, 2 days for TIMI minor
bleeding and TIMI bleeding requiring medical
attention, and 84 days for CABG [15–17]. The
proportion of patients suffering an event,
multiplied by the respective disutility
corrected for event-specific duration of quality
of life impact, was deducted from the overall
quality of life model outcomes. The utility
values applied in the model are provided in
Table 6.T
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Analyses
Costs and quality-adjusted life years (QALYs)
were calculated over a 40-year (i.e., lifetime)
horizon and were presented as mean outcome
per patient allowing estimation of the
incremental cost-effectiveness ratio (ICER).
This approach is standard practice in Markov
cohort modeling. An ICER below the assumed
willingness-to-pay threshold of SEK 500,000
(€56,458) was considered to demonstrate cost-
effectiveness.
A probabilistic sensitivity analysis (PSA)
evaluated the uncertainty generated in the
estimated ICERs by varying all model input
parameters simultaneously for 10,000
iterations. Normal distributions were specified
around the Weibull parameters in the model, all
other parameters were assigned beta
distributions. Univariate analyses varied one
Table 4 Days of lost productivity
Event Number of days of
productivity lost
Conﬁdence
interval
References
MI 80 60–100 Mean sick leave for an MI [25]
IS 137 103–171 Mean sick leave for a stroke [25]
HS/ICH 137 103–171 Assumed same as IS in absence of speciﬁc data
PCI 3 2–4 Weighted average (DRG: E18C and E18E) of inpatient stay
after PCI [41]
CABG 8 6–10 Weighted average (DRG: E07E, E06N and E07A) of
inpatient care after CABG [41]
TIMI major bleed 28 21–35 Patients are recommended to take 4 weeks sick leave for
surgery of perforated peptic ulcer in accordance with the
assumption that major bleed is deﬁned by a GI bleed [38]
TIMI minor bleed 0.5 0.4–0.6 Assumption based on absence from work due to a healthcare
visit
TIMI bleed requiring
medical attention
0.5 0.4–0.6 Assumption based on absence from work due to a healthcare
visit
CABG coronary artery bypass graft, DRG diagnosis related group, GI gastrointestinal, HS hemorrhagic stroke, ICH
intracranial hemorrhage, IS ischemic stroke, MI myocardial infarction, NCD non-cardiovascular death, OCD other
cardiovascular death, PCI percutaneous coronary intervention, TIMI thrombolysis in myocardial infarction
Table 5 Inﬂated (SEK, 2013 values and €, 2014 conversion) cost of added life years adjusted to the ATLAS ACS 2-TIMI
51 trial age distributions [24]
Age (years) 50–64 65–74 75–84 ‡85
Consumption–
production
SEK -15,382
(€-1737)
SEK 21,969
(€2481)
SEK 69,771
(€7878)
SEK 147,683
(€16,676)
ATLAS ACS 2-TIMI 51 Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects
with Acute Coronary Syndrome 2-Thrombolysis in Myocardial Infarction 51 (Clinicaltrials.gov identiﬁer: NCT00809965),
SEK Swedish Krona
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model parameter at a time to investigate the
impact of the upper and lower limits. The
univariate analyses were categorized into non-
efficacy-related and efficacy-related analyses.
The non-efficacy-related analyses varied, for
example, event costs and utility estimates. The
efficacy-related analyses considered the
difference in rates of MI, IS, HS/ICH and other
CV death events between the rivaroxaban ? ST-
APT and ST-APT alone arms. An uncertainty
range of ±25% was applied to all model inputs
in the sensitivity analyses, with the exception of
efficacy data (Fig. 3b), for which a regression
analysis based on the results of the PSA was used
to determine the upper and lower bounds of risk
per event type (i.e., MI, IS, HS/ICH, CV death)
when applying a 95% confidence interval. Plus
and minus 25% of the deterministic value offers
in almost all cases a much wider interval than
would be seen if the interval was based on
Table 6 Utilities applied in model per health state and for transient health states (representing the time since the event)
Event Utility Conﬁdence
interval
Deﬁnition References
Health states
No event (event-free) 0.842 0.632–1.000 No event [14]
MI ﬁrst 6 months 0.779 0.584–0.974 MI [14]
MI second 6 months 0.821 0.616–1.000 Post-MI [14]
MI subsequent 6 month cycles 0.821 0.616–1.000 Post-MI [14]
IS ﬁrst 6 months 0.703 0.527–0.879 Stroke [14]
IS second 6 months 0.748 0.561–0.935 Post-stroke [14, 42]
IS subsequent 6 month cycles 0.792 0.594–0.990 Post-stroke [14, 42]
HS/ICH ﬁrst 6 months 0.703 0.527–0.879 Assumed same as IS in absence of speciﬁc
data
–
HS/ICH second 6 months 0.748 0.561–0.935 Assumed same as IS in absence of speciﬁc
data
–
HS/ICH subsequent 6 month
cycles
0.792 0.594–0.990 Assumed same as IS in absence of speciﬁc
data
–
Transient health states
PCI 0.792 0.594–0.990 PCI (30 days duration) [17]
CABG 0.742 0.557–0.928 CABG (30 days duration) [17]
TIMI major bleeding 0.750 0.563–0.938 GI bleeds (14 days duration) [15]
TIMI minor bleeding 0.800 0.600–1.000 Minor bleeding (2 days duration) [16]
TIMI bleed requiring medical
attention
0.800 0.600–1.000 Minor bleeding (2 days duration) [16]
CABG coronary artery bypass graft, GI gastrointestinal, HS hemorrhagic stroke, ICH intracranial hemorrhage, IS ischemic
stroke, MI myocardial infarction, NCD non-cardiovascular death, OCD other cardiovascular death, PCI percutaneous
coronary intervention, TIMI thrombolysis in myocardial infarction
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published standard errors. The wider interval was
chosen for the analyses because published
standard errors often offer an unrealistic sense
of confidence. For example, in a study by Bagust
et al., a utility estimate is presented for ACS
patients without secondary events of 0.842, with
a standard error of 0.002 [14]. While this may
reflect the study sample from which the utility
was derived, it does not necessarily represent the
average quality of life of a patient from any other
ACS population especially given dependency of
quality of life on age and the size of the
infarction, among other factors. Further
scenarios assessed the model outcomes for
unadjusted probabilities taken directly from the
clinical trial (i.e., reflecting the clinical trial
without manual adjustments to mimic Swedish
clinical practice), assumed a 10-year modeling
time horizon to remove uncertainty around
assumptions far into the future, and applied
zero costs (SEK 0 [€0]) to all treatments
considered in the model. This latter scenario is
designed to mimic a scenario driven by clinical
efficacy and safety only.
RESULTS
Base-Case Analysis
The base-case cost-effectiveness results are
summarized in Table 7. Based on the model,
rivaroxaban 2.5 mg BID given in combination
with ST-APT was associated with a QALY gain of
0.14 and an incremental cost of SEK 10,000
(€1129), yielding a cost per QALY of SEK 71,246
(€8045) when compared with ST-APT alone. The
results showed rivaroxaban 2.5 mg BID to be
associated with fewer non-fatal and fatal events
(incremental costs of SEK -1337 (€-151) and
SEK -226 (€-26) per patient, respectively).
When analyzing only those patients in
stratum 2 of the ATLAS trial (i.e., only
including patients treated with clopidogrel or
ticlopidine in addition to ASA, with or without
Table 7 Results of the base-case analysis (SEK, 2013 prices and €, 2014 conversion)
Rivaroxaban 1 ST-APT ST-APT alone Difference (D)
Costsa
No event (treatment costs only) SEK 164,478 (€18,572) SEK 154,969 (€17,498) SEK 9509 (€1074)
Non-fatal events SEK 374,756 (€42,316) SEK 376,093 (€42,467) SEK -1337 (€-151)
Fatal events SEK 7082 (€800) SEK 7308 (€825) SEK -226 (€-26)
Bleeding SEK 1338 (€151) SEK 494 (€56) SEK 844 (€95)
Revascularization SEK 15,257 (€1723) SEK 14,047 (€1586) SEK 1210 (€137)
Total SEK 562,911 (€63,562) SEK 552, 911 (€64,433) SEK 10,000 (€1129)
Effects
QALYs 10.86 10.72 0.14
ICER
Costs per QALY SEK 71,246 (€8045)
ICER incremental cost-effectiveness ratio, SEK Swedish Krona, ST-APT standard antiplatelet therapy, QALY quality-
adjusted life year
a A 3.0% discount rate was applied to all variables [22]
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rivaroxaban), the ICER is estimated at SEK
97,059 (€11,105). When considering only
those patients not treated with clopidogrel or
ticlopidine (stratum 1 of the trial—ASA
monotherapy, with or without rivaroxaban),
the ICER reduces to SEK 31,149 (€3564).
Rivaroxaban is estimated to be a cost-effective
option for secondary prevention of
cardiovascular events in ACS patients
regardless of the standard of care currently
being received by the patient (ASA
monotherapy or ASA ? clopidogrel or
ticlopidine).
Sensitivity analyses
Uncertainty around the cost-effectiveness
results was demonstrated by plotting
simulations from the PSA on a cost-
effectiveness plane as presented in Fig. 2a.
Almost all of the probabilistic simulations
(92.6%) suggest a QALY gain with rivaroxaban,
with an associated increase in cost (upper right-
hand quadrant of the figure). The probability of
rivaroxaban being cost-effective at a
willingness-to-pay threshold of SEK 500,000
(€56,458) is estimated to be[99.9% (Fig. 2b).
Univariate sensitivity analyses were
performed on all model variables and the
results are presented in Fig. 3. The tornado
graphs show that the base-case analysis was
robust to plausible changes in the input
parameters, with a majority of the parameters
having minimal impact on the overall ICER
(Fig. 3a). In the efficacy-related analysis
(Fig. 3b), the results were most sensitive to
changes in the difference of other CV death
rates between the rivaroxaban 2.5 mg BID ? ST-
APT and ST-APT alone arms. This is not
unexpected as there is a significant CV
mortality benefit associated with rivaroxaban
[11].
Scenario analyses were run to further test
the robustness of the model. Applying
unadjusted probabilities directly from the
clinical trial (not corrected for treatment
discontinuations in the second year and not
interpolated), resulted in a cost per QALY of
SEK 63,855 (€7210).
Applying zero costs to all treatments in the
model (rivaroxaban 2.5 mg BID, clopidogrel/
ticlopidine and ASA), i.e., results are driven by
efficacy alone, provided an ICER of SEK 3500
(€395). Rivaroxaban generated slightly higher
costs in this scenario, due to the increased risk
of expensive stroke events with this treatment,
partially outweighing the savings due to
reductions in MIs and deaths. Additionally,
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Fig. 2 Probabilistic sensitivity analyses (SEK, 2013 values
and €, 2014 conversion): a scatterplot, b cost-effectiveness
acceptability curve. ICER incremental cost-effectiveness
ratio, QALY quality-adjusted life year, SEK Swedish Krona
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rivaroxaban patients were more likely to
experience more subsequent events because
they lived longer, and the conservative
estimate of a SEK 0 cost of non-CV death
reduces the impact of the cost savings that
would be gained with rivaroxaban.
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Assuming a 10-year model time horizon
resulted in an ICER of SEK 83,111 (€9382). The
ICER increased in this scenario because some of
the long-term benefits of rivaroxaban therapy
were not considered in the analysis.
Allowing the treatment effect to vary,
reflecting the clinical trial (without
adjustments), removing the cost disadvantage
associated with rivaroxaban 2.5 mg BID, and
reducing the model time horizon did not alter
conclusions of rivaroxaban 2.5 mg BID in
combination with ST-APT being considered a
cost-effective treatment option.
DISCUSSION
The result from this study demonstrated that,
from a Swedish societal perspective,
rivaroxaban 2.5 mg BID in combination with
ST-APT can be considered a cost-effective
treatment option for the secondary prevention
of ACS in patients with elevated cardiac
biomarkers without a prior history of stroke/
TIA. The base-case results are driven by the
mortality benefit shown in the clinical data of
rivaroxaban 2.5 mg BID. It was observed in the
clinical trial that rivaroxaban 2.5 mg BID in
combination with ST-APT reduced the
occurrence of ACS events; the model
demonstrated that the benefits in terms of life
expectancy and QALY gain were maintained
beyond the trial duration over a 40-year (i.e.,
lifetime) horizon, confirming the advantages of
a dual-pathway strategy in patients with
elevated cardiac biomarkers without a prior
history of stroke/TIA in the secondary
prevention of ACS. Sensitivity analyses were
conducted to test the impact of key
assumptions. The ICER remained within
widely accepted cost-effectiveness thresholds
in these analyses.
This is the first published cost-effectiveness
analysis of rivaroxaban 2.5 mg BID for secondary
prevention of ACS. This model demonstrated
several improvements compared to previous
ACS models used to estimate the cost-
effectiveness of other antithrombotic therapies
[14–17]. The model was able to capture both
single and multiple ACS events, as well as
revascularization procedures. This captured the
full picture of secondary event care in ACS
patients. In addition, IS and HS/ICH were
differentiated, as were fatal and non-fatal events,
thus allowing more accurate estimation of costs in
the model. The model was developed and
calibrated to reflect disease progression in ACS
patients as accurately as possible. Calibration to
life expectancy after a first MI ensured that the
survival following a first MI predicted by the
model was reflective of post-MI survival as
observed in reality. Increased risks of events due
to age and/or the occurrence of earlier events were
also explicitly captured in the model structure.
Many of the model inputs were derived from
Swedish databases, reflecting the perspective of
this study. All of the databases utilized for this
research are national databases and are owned
by Swedish national authorities. The data held
are based on the entire Swedish population and
their coverage is generally considered to be
high. As such, these databases are considered as
strong representations of the population of
interest. Furthermore, the databases have
existed for decades and the data held within
them is widely regarded to be of high quality.
To best reflect the current situation in Sweden,
the most recent data from each database were
used, with at least one data year included to
ensure robustness of model inputs.
However, the approach presented here is not
without its limitations. The model provides a
simplification of what is expected in reality.
Long-term outcomes believed to reflect the
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consequences of therapy in ACS patients were
based on a number of assumptions to capture
natural disease progression. Treatment
durations of 2 years for rivaroxaban and 1 year
for clopidogrel or ticlopidine were assumed to
reflect ESC guidelines [7, 8]; a RRR from the
CURE trial [29] was applied to both treatment
arms to adjust for the removal of clopidogrel or
ticlopidine treatment effect after 1 year. Manual
adjustments to discontinuation rates in the
rivaroxaban arm were required for the second
year of treatment to ensure alignment with
expectations on the use of rivaroxaban in
clinical practice. There is currently no data
available on the real-life use of rivaroxaban in
this patient population. As such, the
discontinuation adjustments applied in the
evaluation are based on expert opinion.
Further, the model does not consider the long-
term impact of non-fatal/non-ICH bleeding
events beyond the duration of treatment as
this was believed to have marginal impact on
the overall model outcomes. In the absence of
specific HS/ICH estimates, the costs and utilities
applied to patients experiencing IS were also
applied to those with HS/ICH.
CONCLUSION
The analysis suggests that rivaroxaban 2.5 mg
BID provides a cost-effective treatment strategy
in a Swedish societal setting for the secondary
prevention of ACS in patients with elevated
biomarkers without prior stroke/TIA, mainly
driven by a benefit in terms of reduced
mortality as demonstrated in the ATLAS ACS
2-TIMI 51 trial. This analysis may help to
support the combination of ST-APT and
rivaroxaban 2.5 mg BID for the secondary
prevention of ACS events, as recommended by
the ESC STEMI guidelines in patients with low
bleeding risk [8]. The conclusion of cost-
effectiveness holds, regardless of the standard
of care currently being received by the patient
(ASA monotherapy or ASA ? clopidogrel or
ticlopidine).
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